



Open Government Impact Statement

80th Oregon Legislative Assembly
2020 Regular Session

Measure: SB 1535 - B

Only impacts on Original or Engrossed
Versions are Considered Official

Prepared by: Cameron D. Miles
Date: 3/2/2020

SUMMARY

Requires Department of Consumer and Business Services to investigate methods for collecting information about rebates and markups used in pharmaceutical supply chain and to report to interim committees of Legislative Assembly recommendations for collecting information.

Authorizes department to access, use and disclose data from all payer, all claims database under specified conditions.

Modifies increase in price of prescription drug that triggers pharmaceutical manufacturer's obligation to report data under Prescription Drug Price Transparency Act.

Allows department to disclose information about consumers' notifications of increases in prices of prescription drugs but not personally identifiable information about consumers.

Modifies membership of, charge to and reporting requirements for Task Force on the Fair Pricing of Prescription Drugs. Extends sunset of task force to December 31, 2022.

Declares emergency, effective on passage.

OPEN GOVERNMENT IMPACT

Legislative Counsel has not adopted standards for drafting measures that establish exemptions from disclosure of public records.

This measure exempts from public disclosure personally identifiable information obtained by the Department of Consumer and Business Services from the all payer, all claims database and from consumer notifications regarding increases in prices of prescription drugs.

If those public records that could be subject to public disclosure were instead subject to mandatory disclosure under public records law, health care data and information regarding consumers reporting price increases for prescription drugs would more likely be made public.